UP­DATE: For­ma takes aim at Agios with new AML com­plete re­mis­sion da­ta

For­ma Ther­a­peu­tics went pub­lic this year and raised $320 mil­lion in large part on the strength of their Phase I/II sick­le cell pro­gram. But their non-core pro­grams al­so held promise, in­clud­ing that they could go toe-to-toe with Agios on acute myeloid leukemia. To­day, the Mass­a­chu­setts biotech an­nounced they’ve done that — al­most to a tee.

On Tues­day, For­ma an­nounced that, in a piv­otal Phase II study, its AML drug olu­tasi­denib led to a com­plete re­mis­sion in 30% of re­lapsed or re­frac­to­ry IDH1m-pos­i­tive pa­tients. Com­bine that with a 3% rate of com­plete re­mis­sion with par­tial hema­to­log­ic re­cov­ery, and you get a 33% CR/CR+ rate — vir­tu­al­ly iden­ti­cal with the 32.7% CR/CR+ rate that Agios’ Tib­so­vo showed in a piv­otal study on these pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.